428 related articles for article (PubMed ID: 24667960)
1. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.
Riddell SR; Sommermeyer D; Berger C; Liu LS; Balakrishnan A; Salter A; Hudecek M; Maloney DG; Turtle CJ
Cancer J; 2014; 20(2):141-4. PubMed ID: 24667960
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
[TBL] [Abstract][Full Text] [Related]
3. Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells.
Maher J
Curr Gene Ther; 2014 Feb; 14(1):35-43. PubMed ID: 24365143
[TBL] [Abstract][Full Text] [Related]
4. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
[TBL] [Abstract][Full Text] [Related]
5. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Kochenderfer JN; Rosenberg SA
Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
[TBL] [Abstract][Full Text] [Related]
6. The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
Nair R; Neelapu SS
Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399
[TBL] [Abstract][Full Text] [Related]
7. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Makita S; Yoshimura K; Tobinai K
Cancer Sci; 2017 Jun; 108(6):1109-1118. PubMed ID: 28301076
[TBL] [Abstract][Full Text] [Related]
8. [Adoptive immunotherapy utilizing anti-CD19 chimeric antigen receptor T-cells for B-cell malignancies].
Oh I; Oh Y; Ohmine K
Rinsho Ketsueki; 2016; 57(11):2365-2372. PubMed ID: 27941287
[TBL] [Abstract][Full Text] [Related]
9. CARTs to the rescue: therapeutic potential of chimeric antigen receptor T-cells in patients with B-cell malignancies.
Tam CS
Leuk Lymphoma; 2013 Feb; 54(2):215-6. PubMed ID: 22950939
[No Abstract] [Full Text] [Related]
10. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells.
Jakobczyk H; Sciortino F; Chevance S; Gauffre F; Troadec MB
Int J Pharm; 2017 Nov; 532(2):813-824. PubMed ID: 28764981
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
Levin A; Shah NN
Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
[TBL] [Abstract][Full Text] [Related]
14. Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells.
Cheadle EJ; Hawkins RE; Batha H; Rothwell DG; Ashton G; Gilham DE
J Immunother; 2009 Apr; 32(3):207-18. PubMed ID: 19242379
[TBL] [Abstract][Full Text] [Related]
15. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
16. Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety.
Hao L; Li T; Chang LJ; Chen X
Curr Med Chem; 2019; 26(17):3068-3079. PubMed ID: 28762313
[TBL] [Abstract][Full Text] [Related]
17. Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.
Kiani J; Naderi M; Torabi-Rahvar M; Ranjbar A; Aghayan HR; Janzamin E; Ahmadbeigi N
Arch Iran Med; 2019 Jan; 22(1):7-10. PubMed ID: 30821155
[TBL] [Abstract][Full Text] [Related]
18. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
[TBL] [Abstract][Full Text] [Related]
19. What CAR Will Win the CD19 Race?
Quintás-Cardama A
Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581
[TBL] [Abstract][Full Text] [Related]
20. Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma.
Sakai O; Igase M; Mizuno T
Vet Comp Oncol; 2020 Dec; 18(4):739-752. PubMed ID: 32329214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]